CD8A and neoplasm: For instance, Salmon et al. have shown that FLT3L/poly I:C treatment synergized with PD-L1 blockade to prevent the secondary melanoma lesions after Braf inhibition, as well as provide protection against tumor re-challenge, indicated the generation of memory CD8 T cell responses after CD8 T cell priming (93).